Skip to main content

Partnerships: Industry & Academic

Engaging Industry and Academic Partners

CCTG is know for cancer clinical trial research and is the world's largest cooperative collaborative oncology group. Our success is realized through our network of investigators who develop scientifically important and meaningful trials, conducted both rapidly and to rigorous standards. With over 40 years of experience there is no network that rivals the depth and breadth of operations with a global reputation for rapid execution of quality clinical trials.

Partnerships

National and international collaboration

Industry partnerships

While CCTG trials are independently conducted, analyzed and reported. Pharmaceutical or academic drug manufacturers provide CCTG access to their investigational new drugs because they recognize the high quality research being conducted through the group.

 

EN12 RAINBO-ORANGE successful CIHR Project Grant funding

EN12 RAINBO-ORANGE successful CIHR Project Grant funding

The EN12 RAINBO-ORANGE clinical trial was awarded $1,575,898 through the CIHR Project Grant to investigate if surgery followed by radiotherapy and a type of oral endocrine therapy called progestins will lead to similar cancer control as surgery followed by radiotherapy and chemotherapy in patients with NSMP, estrogen receptor-positive endometrial cancer (EC).

More >>
 
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer

CCTG, EORTC and UK3CR welcome the G7 Leaders’ announcement recognizing cancer as a global priority.

More >>
 
Drs. Raphael, Maleki, and Silverman

Largest-ever Canadian clinical trial tests “poop pills” to improve immunotherapy for lung cancer

For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.

More >>
 
Dr Nappi on stage at ASCO 2026 presenting interim results for CCTG trial

A simple blood test may detect tumor relapse in patients with early-stage germ cell tumors

The interim results of the GCC.1 (S1823) study were presented at ASCO 2026 during the Genitourinary Cancer Session. The study focuses on patients with early-stage germ cell tumors and the blood biomarker microribonucleic acid (miRNA) 371a-3p (called miR371). The presence of miR371 may allow clinicians to identify patients at higher risk of relapse earlier and more accurately than current monitoring approaches.

More >>